HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums

This article was originally published in The Rose Sheet

Executive Summary

Purchase of Tristar fragrances may provide opportunity to expand distribution of mass market brands into Wal-Mart, CEO Jean Madar says during Q1 sales and earnings release May 14. Firm's wholly-owned subsidiary recently received approval of purchase from San Antonio Bankruptcy Court and expects to close definitive agreement by end of the month (1"The Rose Sheet" May 6, 2002, In Brief). Inter Parfums mass market sales increased 9% on strong performances by Aziza and Intimate health and beauty aids, while prestige fragrances were down 10% in constant dollars, reflecting fewer launches compared with same period last year. Net sales declined 8.5% to $28.4 mil. and net income fell 1% to $2 mil...

You may also be interested in...



Inter Parfums buy

Sales from acquired Tristar mass market fragrance brands could reach $15 mil. within 12 months, fragrance marketer says. Inter Parfums' wholly-owned subsidiary, Jean Philippe Fragrances, received approval from San Antonio, Texas bankruptcy court to buy certain Tristar trademarks and intellectual property for $3.5 mil. and inventory for $4.7 mil., firm announces May 1. Tristar's fragrance portfolio includes Royal, Royal Crown II, Regal and Club Exclusive. Formal purchase agreement to be signed shortly; deal is expected to close by June 1. Fragrance Impressions, a newly formed company owned by Tristar management, will purchase remaining assets of Tristar. Jean Philippe announced its bid in March following Tristar's Chapter 11 filing (1"The Rose Sheet" March 18, 2002, p. 3)...

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel